Healthcare

HB 195 revises Montana’s cap on non-monetary damages (like pain, suffering, and emotional distress) in medical malpractice cases. It immediately raises the limit from $250,000 to $300,000, with scheduled annual increases: $350,000 in 2026, $400,000 in 2027, $450,000 in 2028, $500,000 in 2029, and 2% annual increases thereafter. The cap applies per patient per incident and is determined by the date the claim was first filed (with the medical panel or in court), not the trial date. This directly affects patients filing medical malpractice claims and healthcare providers defending such cases.

HB 41 adds gabapentin to Montana's Schedule V list of controlled substances under the "depressants" category. This change directly affects medical providers who prescribe gabapentin (used for nerve pain, seizures, and other conditions), pharmacists who dispense it, and patients using the medication. The bill amends Montana Code § 50-32-232 to explicitly include gabapentin - identified by its chemical name "1-(aminomethyl)cyclohexaneacetic acid" - in Schedule V depressants alongside drugs like pregabalin. This policy update standardizes gabapentin's regulatory classification without altering its medical use or prescribing rules.